The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Blood

Volumn 127, Issue 17, 2016, Pages 2157-2160

  Olombel, Guillaume ^a   Guerin, Estelle ^a   Guy, Julien ^b   Perrot, Jean Yves ^c   Dumezy, Florent ^d   de Labarthe, Adrienne ^e   Bastie, Jean Noël ^b   Legrand, Ollivier ^f   Raffoux, Emmanuel ^e   Plesa, Adriana ^g   Wagner Ballon, Orianne ^h   Cornet, Edouard ⁱ   Salaun, Véronique ⁱ   Preudhomme, Claude ^d   Thomas, Xavier ^j   Pautas, Cécile ^h   Chantepie, Sylvain ⁱ   Turlure, Pascal ^a   Castaigne, Sylvie ^k   Dombret, Hervé ^e   Feuillard, Jean ^a   more..

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ CAEN UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

^k CENTRE HOSPITALIER DE VERSAILLES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; GEMTUZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE MYELOID LEUKEMIA; CANCER PATIENT; DRUG EFFECT; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SIALIC ACID BINDING IG-LIKE LECTIN 3; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85016775310     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-689976     Document Type: Letter

References (20)

1. Sievers EL, Larson RA, Stadtmauer EA, et al; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13): 3244-3254.
2. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
3. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4): 369-377.
4. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924-3931.
5. Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
6. Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamicin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]. Blood. 2011;118(21). Abstract 79.
7. 2 combined with induction chemotherapy in younger patients with AML: data from the UK NCRI AML17 trial [abstract]. Blood. 2014;124(21). Abstract 2308.
8. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996.
9. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295-1302.
10. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia. 2010;24(1):74-80.
11. Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(1) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192-5197.
12. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168-4170.
13. Castaigne S, Pautas C, Terré C, et al. Final analysis of the ALFA 0701 study [abstract]. Blood. 2014;124(21). Abstract 376.
14. Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72(Suppl 1):S14-S22.
15. Kristensen JS, Hokland P. Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia. Leuk Res. 1991;15(8):693-700.
16. De Propris MS, Raponi S, Diverio D, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10):1548-1551.
17. Ehninger A, Kramer M, Röllig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.
18. Pollard JA, Alonzo TA, Loken M, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16): 3705-3711.
19. Rigolin GM, Lanza F, Ferrari L, Castoldi G. CD341/CD331 blast cells: correlation with FAB subtypes. Leuk Lymphoma. 1995;18(Suppl 1):43-48.
20. Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 2003; 17(3):515-527.